These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35786664)

  • 21. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
    Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
    Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma.
    Maftouh M; Belo AI; Avan A; Funel N; Peters GJ; Giovannetti E; Van Die I
    Oncotarget; 2014 Jul; 5(14):5335-49. PubMed ID: 24977327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXO1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling.
    Ling J; Wang F; Liu C; Dong X; Xue Y; Jia X; Song W; Li Q
    J Exp Clin Cancer Res; 2019 Apr; 38(1):179. PubMed ID: 31027497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.
    Pai P; Rachagani S; Lakshmanan I; Macha MA; Sheinin Y; Smith LM; Ponnusamy MP; Batra SK
    Mol Oncol; 2016 Feb; 10(2):224-39. PubMed ID: 26526617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
    Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
    Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
    Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
    Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer.
    Zhang Q; Lou Y; Zhang J; Fu Q; Wei T; Sun X; Chen Q; Yang J; Bai X; Liang T
    Mol Cancer; 2017 Jul; 16(1):119. PubMed ID: 28705232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High tissue MMP14 expression predicts worse survival in gastric cancer, particularly with a low PROX1.
    Kasurinen A; Gramolelli S; Hagström J; Laitinen A; Kokkola A; Miki Y; Lehti K; Yashiro M; Ojala PM; Böckelman C; Haglund C
    Cancer Med; 2019 Nov; 8(16):6995-7005. PubMed ID: 31560170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
    Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
    Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and prognostic value of transcription factor PROX1 in colorectal cancer.
    Skog M; Bono P; Lundin M; Lundin J; Louhimo J; Linder N; Petrova TV; Andersson LC; Joensuu H; Alitalo K; Haglund CH
    Br J Cancer; 2011 Oct; 105(9):1346-51. PubMed ID: 21970873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PROX1 Was Associated with LGR5 and Wnt Signaling and Contributed to Poor Prognosis in Gastric Cancer.
    Nakazawa N; Sohda M; Ide M; Shimoda Y; Tateno K; Watanabe T; Sano A; Sakai M; Yokobori T; Ogawa H; Oyama T; Shirabe K; Saeki H
    Oncology; 2022; 100(11):569-575. PubMed ID: 36103842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner.
    Ren R; Yu J; Zhang Y; Wang SF; Guo X; Shen M; Xu MD; Jiang M; Zhi Q; Chen K; Tao M; Wu MY; Gu DM; Li W
    Pancreas; 2019 Sep; 48(8):1003-1014. PubMed ID: 31404031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
    Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
    Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
    Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma.
    Okubo S; Kojima M; Matsuda Y; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Mino-Kenudson M; Takahashi S
    Sci Rep; 2019 Nov; 9(1):17145. PubMed ID: 31748528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.